Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”


HHS - 5248 - National Cancer Institute Council of Research Advocates - Authorized by Law
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameNational Cancer Institute Council of Research AdvocatesAgency NameDepartment of Health and Human Services
Fiscal Year2022Committee Number5248
Original Establishment Date8/17/1998Committee StatusChartered
Actual Termination Date Committee URLhttp://deainfo.nci.nih.gov/advisory/ncra/ncra.htm
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*16
Current Charter Date8/17/2022Designated Fed Officer Position Title*ACTING DIRECTOR, OFFICE OF ADVOCACY RELATIONS
Date Of Renewal Charter8/17/2024Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*AMY
Exempt From Renewal*NoDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*WILLIAMS
Establishment Authority*Authorized by LawDesignated Federal Officer Suffix
Specific Establishment Authority*42 U.S.C. 285a-2(b)(7)Designated Federal Officer Phone*240-781-3406
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*240-541-4517
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*williaam@mail.nih.gov
Committee Type*Continuing
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The role the National Cancer Institute’s Council of Research Advocates (NCRA) is to identify and respond to issues and challenges facing the Institute and the cancer research community, at the request of the NCI Director. Board members provide informed, non-scientific perspectives relevant to promoting research outcomes that are in the best interest of patients. This includes identifying new approaches, promoting innovation, recognizing unforeseen risks or barriers, and identifying unintended consequences that could result from NCI or other federal government decisions or actions, as well as enhancing input, optimizing outreach, and promoting strong collaborations, all with respect to non-scientist stakeholders, in the interest of meeting common Institute and community goals. In FY2022, NCRA held three virtual meetings on March 9, 2022; June 29, 2022; and September 28, 2022. Members were provided updates from the NCI Director, NCI Acting Director, updates on budgetary and legislative matters, updates on the NCI Office of Cancer Survivorship and the NCI Division of Cancer Prevention, updates on national-level research advocacy training programs, an update on the NCI COVID-19 in Cancer Patients Study (NCCAPS), an update on the NCI Annual Plan for FY24, and an update on the activities of the White House Office of Science and Technology Policy before providing their thoughts, insights, and observations to the NCI Director, NCI Acting Director, and other senior leaders.
How is membership balanced?*The Committee consists of up to 16 members, including the Chair appointed by the Director, NCI. The membership consists of cancer research advocates who are involved in the cancer experience and possess an expert understanding of non-scientific burdens to cancer research as well as of the perspectives and dynamics of the research, patient, policy, and advocacy communities interested in cancer research and cancer care delivery. This expert understanding will have been gained through experience working in the cancer advocacy field, affiliation with a cancer related professional society, affiliation with a research foundation involved in cancer research or healthcare, experience as a health care professional focused on the study of cancer and other related diseases, or experience serving as a thought-leader in an area related to cancer research and care delivery.
How frequent & relevant are cmte mtgs?*Meetings of the full Committee will be held approximately 2-3 times within a fiscal year. The Committee met three times during this reporting period to advise and make recommendations to the Director, NCI, from the perspective and viewpoint of cancer research advocates on a wide variety of issues, programs, and research priorities. In FY2022, the NCRA meetings were held on March 9, 2022; June 29, 2022; and September 28, 2022 (all virtual).
Why advice can't be obtained elsewhere?*The membership consists of cancer research advocates who possess an expert understanding of non-scientific burdens related to cancer research, as well as of the perspectives and dynamics of the research, patient, policy, and advocacy communities interested in cancer research and cancer care delivery. The advice is not available from NCI staff or existing committees.
Why close or partially close meetings?N/A
Recommendation RemarksReports: This committee did not produce any public reports.

Vacancies/Members Rotating Off/On-Boarding: The committee has four vacancies. Two members rotated off (Angelica Davis and Jennifer Pegher) and four members were on-boarded (Victoria Buenger, Melissa Buffalo, Nathaniel Ferre, and Joya Harris). This is why the Charter states up to 16 members, but this ACR lists 12.

Members: The term start date for Anjelica Davis's term as Chair was reported incorrectly on the FY21 ACR. As such, her term start date is different then what was reported in FY21. Annie Ellis was reassigned as Chair on 7/1/2022.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*NoAction Reorganize Priorities*No
Outcome Trust In GovernmentYesAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchNoAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionYesAction CommentThe Committee makes recommendations to federal staff by responding to issues and challenges facing the Institute and cancer research community and provides advice to the NCI Director around approaches to enhance community input, optimize community outreach, and promote effective collaborations that will help address these challenges and lead to improved research outcomes. As a result, specific topics of interest to the cancer research advocacy community are defined and integrated into the NCI’s Office of Advocacy Relations communications strategy and plan.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherYesNumber Of Grants Reviewed0
Outcome CommentPublic engagement in the research process.Number Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentNCI supports basic, translational and clinical research which often takes many years to deliver clinically applicable scientific advances.Grants Review CommentN/A
Number Of Recommendations*97Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentIn FY22, NCRA made general recommendations. The NCRA is an advisory committee designed to provide perspective, feedback, and ideas to the NCI. NCRA also provides a forum for government and private groups to work together to address critical issues that affect NCI’s work.Access Agency WebsiteYes
% of Recs Fully Implemented*40.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe percentage of recommendations implemented as stated above were developed at the time the Annual Comprehensive Report was prepared.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*40.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe percentage of recommendations implemented as stated above were developed at the time the Annual Comprehensive Report was prepared.Access OtherYes
Agency Feedback*YesAccess CommentInformation on the NCRA can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at http://deainfo.nci.nih.gov/advisory/ncra/ncra.htm. Each NCI committee’s charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint presentations and reports is located here. Additionally, the public may view the NCRA meetings (both live and on demand) via the NIH Videocast at the following website: http://videocast.nih.gov/.
Agency Feedback Comment*E-mail updates and presentations at the meetings. NCI leadership gave feedback directly to the NCRA through meetings with the full advisory group. The NCI community is made aware of NCRA activities through NCI’s Office of Advocacy Relations. Information is provided to the public at each meeting. The public can view information related to the Committee through the NCRA’s official website.Narrative Description*The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. The NCI Council of Research Advocates (NCRA), is the only federal advisory committee comprised of advocate leaders at NCI. NCRA members are chosen for their expert knowledge of issues of importance to the cancer research community. The NCRA identifies and responds to issues and challenges facing the Institute and cancer research community and provides advice to the NCI Director around approaches to enhance community input, optimize community outreach, and promote effective collaborations that will help address these challenges and lead to improved research outcomes. In addition, NCRA members bring their unique skills and perspectives by identifying new approaches, promoting innovation, recognizing unforeseen risks or barriers, and identifying unintended consequences that could result from NCI decisions. The NCRA focuses on enhancing community input, optimizing community outreach, and promoting strong collaborations to improve research outcomes.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$5,800.00Est Payments to Non-Fed Members Next FY*$5,800.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$67,745.00Estimated Payments to Federal Staff*$69,574.00
Payments to Consultants*$600.00Est. Payments to Consultants Next FY*$600.00
Travel Reimb. For Non-Federal Members*$0.00Est Travel Reimb Non-Fed Members nextFY*$17,219.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$5,740.00
Other Costs$15,925.00Est. Other Costs Next FY*$16,085.00
Total Costs$90,070.00Est. Total Next FY*$115,018.00
Date Cost Last Modified11/10/2022 8:51 AMEst. Fed Staff Support Next FY*0.40
Federal Staff Support (FTE)*0.40Est Cost RemarksProjected costs for FY23 were increased in the event that in-person/hybrid meetings resume.
Cost RemarksMeetings were held virtually in FY22 due to the ongoing COVID-19 pandemic as such the FY22 Operating Costs are lower than what was projected on the FY21 FOP. The operating costs for FY22 are lower than those reported for FY21 because there were no working group meetings. The federal staff cost and total staff support differences between FY21 and FY22 are due to staffing changes and the realignment of work in support of NCRA. Projected costs for FY23 were increased in the event that in-person/hybrid meetings resume.  
Hide Section - Interest Areas

Interest Areas

Category
Area
Health
Treatment
Medicine
Diseases
Health and Health Research
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-040284National Cancer Institute Council of Research Advocates2021
 COM-038560National Cancer Institute Council of Research Advocates2020
 COM-036432National Cancer Institute Council of Research Advocates2019
 COM-034638National Cancer Institute Council of Research Advocates2018
 COM-001935National Cancer Institute Council of Research Advocates2017
 COM-002330National Cancer Institute Council of Research Advocates2016
 COM-004093National Cancer Institute Council of Research Advocates2015
 COM-004394National Cancer Institute Council of Research Advocates2014
 COM-005926National Cancer Institute Director's Consumer Liaison Group2013
 COM-006661National Cancer Institute Director's Consumer Liaison Group2012
 COM-007985National Cancer Institute Director's Consumer Liaison Group2011
 COM-008816National Cancer Institute Director's Consumer Liaison Group2010
 COM-010242National Cancer Institute Director's Consumer Liaison Group2009
 COM-010703National Cancer Institute Director's Consumer Liaison Group2008
 COM-011939National Cancer Institute Director's Consumer Liaison Group2007
 COM-012658National Cancer Institute Director's Consumer Liaison Group2006
 COM-014082National Cancer Institute Director's Consumer Liaison Group2005
 COM-014785National Cancer Institute Director's Consumer Liaison Group2004
 COM-015869National Cancer Institute Director's Consumer Liaison Group2003
 COM-016739National Cancer Institute Director's Consumer Liaison Group2002
 COM-017877National Cancer Institute Director's Consumer Liaison Group2001
 COM-018431National Cancer Institute Director's Consumer Liaison Group2000
 COM-019771National Cancer Institute Director's Consumer Liaison Group1999
 COM-020460National Cancer Institute Director's Consumer Liaison Group1998